FORT WORTH, Texas, June 8, 2022 /PRNewswire/ -- Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will present four scientific presentations at the 2022 Vegas Cosmetic Surgery (VCS) & Aesthetic Dermatology Annual Symposium to showcase the latest advancements surrounding its approved and investigational product upda

• Strong clinical data supporting Alluzience^® (abobotulinumtoxinA, ABO), the first liquid, ready-to-use neuromodulator as an effective and well-tolerated treatment for glabellar (frown) lines, with a rapid onset and long duration of action of up to six months
• Data confirming that Dysport^® was consistently efficacious for the treatment of frown lines, was wel

Galderma will be showcasing the latest data from its world-leading, science-based aesthetics portfolio at the American Society for Dermatologic Surgery (ASDS) 2024 Annual Meeting, held in Florida from October 17-20.

Details on the six abstracts to be presented by Galderma at the ASDS 2024 Annual Meeting can be found below.

Galderma presented eight abstracts in support of innovative aesthetics solutions and pipeline, including post-marketing safety surveillance study abstract named to “Best of Cosmetic Oral Abstracts” list

Ad hoc announcement pursuant to Art. 53 LR

Zug, Switzerland, March 5, 2026 – Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025.